Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary objective:

• Develop and validate a tool towards patients with chronic hepatitis C genotype 1 and 4 to allow optimize treatment.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
• Treatments: Interferon-alpha; Peginterferon alfa-2a; Ribavirin

Criteria

Inclusion Criteria:

• Patients with > 18 years old.

• Patients diagnosed with chronic hepatitis C in the presence of HCV RNA in plasma that meet criteria for initiating antiviral therapy in routine clinical practice conditions.

• Patients Genotype 1 and 4.

• Patients with the results of all the factors evaluable at the time of inclusion.

• Patients who have accepted their participation in the study through informed consent.

Exclusion Criteria:

• Patients previously treated with interferon (IFN) and ribavirin (RBV).

• Patients with genotype 2, 3, 5 and 6.

• Patients with co-infection with hepatitis B.

• Patients with other liver diseases.

• Patients with any contraindications to the drugs used in the treatment of hepatitis C.